5:40 PM
 | 
Sep 24, 2009
 |  BC Extra  |  Company News

Dendreon gives Provenge update

Dendreon Corp. (NASDAQ:DNDN) said it plans to submit an amendment to its BLA for Provenge sipuleucel-T to treat advanced prostate cancer...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >